549P - Prognostic factors and clinical outcomes of malignant pleural mesothelioma in a real world-setting: An Asian cohort

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Bioethics, Legal, and Economic Issues
Mesothelioma
Presenter Ting-Hui Wu
Citation Annals of Oncology (2016) 27 (suppl_9): ix177-ix178. 10.1093/annonc/mdw600
Authors T. Wu1, L.J. Lee2, C. Yuan3, T.W. Chen1
  • 1Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 2National Institute Of Environmental Health Sciences, National Health Research Institutes, 35053 - Miaoli/TW
  • 3Department Of Pathology, National Taiwan University Hospital, 100 - Taipei/TW

Abstract

Background

There are scarce reports on the treatment and outcome of patients with malignant pleural mesothelioma (MPM) in Asia. This study aimed to assess the treatment pattern and identify significant prognostic factors in MPM patients in a real-world setting.

Methods

Medical records of patients with histologically proven MPM diagnosed between 1977 and 2015 at the National Taiwan University Hospital were reviewed. Variables including age, gender, asbestos exposure, smoking history, histology subtype, staging (AJCC 7th), and treatment received were recorded. All patients were followed until death or October 31st, 2015, whichever occurred earlier. Survival and prognostic factors were analyzed by Kaplan-Meir method and Cox proportional hazard model.

Results

A total of 82 patients were identified, including 59 men and 23 women. A trend of increasing newly diagnosed MPM cases was observed over the 38-year span. The median overall survival for stage I/II and stage III/IV patients was 33.4 and 7.3 months, respectively. Significant predictors for better survival included stage I/II (hazard ratio [HR] 0.29, 95% CI 0.14-0.59, p 

Conclusions

This is one of the largest case series of MPM with detailed patient data reported in Asia outside of Japan. Significant prognostic factors for MPM included stage, age, and histology subtype. In patients with advanced disease, systemic treatment may confer a better outcome.

Clinical trial indentification

Legal entity responsible for the study

National Taiwan University Hospital

Funding

National Taiwan University Hospital

Disclosure

All authors have declared no conflicts of interest.